INmune Bio
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of INmune Bio generated cash of -$11,980,000, which is more than the previous year. Cash used in financing activities reached the amount of -$4,225,000 last year. Net change in cash is therefore -$16,305,000.
Cash Flow
| 2015 | -18.11K | 0 | 30K |
|---|---|---|---|
| 2016 | -317.37K | 0 | 450K |
| 2017 | -761.83K | -100K | 2.05M |
| 2018 | -2.05M | 0 | 900K |
| 2019 | -5.38M | 0 | 12.20M |
| 2020 | -8.94M | 0 | 23.89M |
| 2021 | -28.50M | -15M | 96.35M |
| 2022 | -22.68M | 0 | 729K |
| 2023 | -11.98M | 0 | -4.22M |
INMB Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 52.15M | 74.81M | 21.96M | 6.99M | 186.20K | 1.37M | 141.65K | 11.88K | 0 |
Operating activities | |||||||||
Net income | -30.00M | -27.29M | -30.34M | -12.09M | -7.67M | -12.44M | -831.48K | -277.49K | -48.86K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 7.36M | 7.14M | 4.79M | 3.11M | 4.09M | 0 | 199.55K | 0 | 120K |
| Deferred income tax benefit | 7.36M | 7.14M | 4.79M | 3.11M | 4.09M | 0 | 199.55K | 0 | 120K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 6.01M | -2.95M | -3.70M | -1.15M | 2.22K | 0 | -67.12K | 0 | 0 |
Inventories | 0 | 2.95M | 3.70M | 1.15M | -2.22K | 0 | 0 | 0 | 0 |
Accounts payable | 2.72M | 1.40M | 2.26M | 1.07M | -131.67K | 514.04K | 238.90K | 220.06K | 0 |
Cash generated by operating activities | -11.98M | -22.68M | -28.50M | -8.94M | -5.38M | -2.05M | -761.83K | -317.37K | -18.11K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -15M | 0 | 0 | 0 | -100K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | -15M | 0 | 0 | 0 | -100K | 0 | 0 |
Financing activities | |||||||||
Common Stock Issued | 775K | 699K | 81.40M | 24.90M | 12.20M | 900K | 2.05M | 100K | 30K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -1.01M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -5M | 0 | -14.95M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -4.22M | 729K | 96.35M | 23.89M | 12.20M | 900K | 2.05M | 450K | 30K |
Net Change In Cash | -16.30M | -22.65M | 52.84M | 14.97M | 6.80M | -1.18M | 1.22M | 129.77K | 11.88K |
Cash at end of period | 35.84M | 52.15M | 74.81M | 21.96M | 6.99M | 186.20K | 1.37M | 141.65K | 11.88K |
| Data source | Data source | Data source | Data source | Data source | Data source |